
I-BET151
CAS No. 1300031-49-5
I-BET151 ( GSK1210151A | I-BET 151 | GSK-1210151A )
产品货号. M11204 CAS No. 1300031-49-5
I-BET151 (GSK1210151A) 是一种有效的选择性 BET 溴结构域抑制剂。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
2MG | ¥478 | 有现货 |
![]() ![]() |
5MG | ¥786 | 有现货 |
![]() ![]() |
10MG | ¥948 | 有现货 |
![]() ![]() |
25MG | ¥1725 | 有现货 |
![]() ![]() |
50MG | ¥2892 | 有现货 |
![]() ![]() |
100MG | ¥4317 | 有现货 |
![]() ![]() |
500MG | ¥9639 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称I-BET151
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述I-BET151 (GSK1210151A) 是一种有效的选择性 BET 溴结构域抑制剂。
-
产品描述I-BET151 (GSK1210151A) is a potent, selective BET bromodomain inhibitor with IC50 of 0.5, 0.25 and 0.79 uM for BRD2, BRD3 and BRD4 in FP assays, shows no effect on the 23 other bromodomain proteins including MLL; demonstrates potent efficacy against cell lines harbouring different MLL-fusions (MOLM13 cell IC50=120 nM, MV4:11 cell IC50=26 nM), induices early cell cycle arrest and apoptosis, selectively abrogates BRD3/4 recruitment to chromatin;shows significant therapeutic value and survival benefit in mouse models of murine MLL-AF9 and human MLL-AF4 leukaemia.
-
体外实验Cell Viability Assay Cell Line:H929 cells Concentration:1 μM Incubation Time:72 hours Result:Displays the majority of live cells resided in the G0 phase and commensurate with a dose- and time-dependent decrease in cell proliferation and abrogation of bromodeoxyuridine incorporation.Cell Proliferation Assay Cell Line:H929 cells Concentration:100 nM Incubation Time:72 hours Result:Caused a significant dose- and time-dependent decrease in the proportion of myeloma cells in S/G2 phase.
-
体内实验Animal Model:Mice (model of subcutaneous myeloma)Dosage:50 mg/kg Administration:I.p.; daily for 21 daysResult:Reduced rate of tumor size doubling than vehicle-treated mice.
-
同义词GSK1210151A | I-BET 151 | GSK-1210151A
-
通路Chromatin/Epigenetic
-
靶点Bromodomain
-
受体BRD2|BRD3|BRD4
-
研究领域Cancer
-
适应症——
化学信息
-
CAS Number1300031-49-5
-
分子量415.4445
-
分子式C23H21N5O3
-
纯度>98% (HPLC)
-
溶解度10 mM in DMSO
-
SMILESO=C(N1[C@@H](C2=NC=CC=C2)C)NC3=C1C4=CC(OC)=C(C5=C(C)ON=C5C)C=C4N=C3
-
化学全称2H-Imidazo[4,5-c]quinolin-2-one, 7-(3,5-dimethyl-4-isoxazolyl)-1,3-dihydro-8-methoxy-1-[(1R)-1-(2-pyridinyl)ethyl]-
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Dawson MA, et al. Nature. 2011 Oct 2;478(7370):529-33.
2. Mirguet O, et al. Bioorg Med Chem Lett. 2012 Apr 15;22(8):2963-7.
3. Chaidos A, et al. Blood. 2014 Jan 30;123(5):697-705.
4. Wyspiańska BS, et al. Leukemia. 2014 Jan;28(1):88-97.